- World Pharma News Home » Product » Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission
(a free service delivered by FeedBurner)
Boehringer Ingelheim announced that the European Commission has granted marketing authorisation of the novel, oral direct thrombin inhibitor, Pradaxa® (dabigatran etexilate) in all 27 EU member states. It is anticipated that Pradaxa® will be launched in Germany and the United Kingdom in the coming weeks. Pradaxa® is approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments